Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q3 2016 · 10-Q
Revenue$1.09M$1.09M−57.3% vs Q3 2015 Net Income-$403.00K-$403.00KN/M vs Q3 2015 EPS Diluted-$0.02-$0.02N/M vs Q3 2015 Operating Income-$375,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,530N/M Margins · derivedOperating margin-34.6%−14.9 pt vs Q3 2015
Net margin-37.1%−13.9 pt vs Q3 2015
ended Dec 31, 2015 · filed Feb 16, 2016 · 47 d after period end